POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.260
https://www.valueinhealthjournal.com/article/S1098-3015(21)02055-6/fulltext
Title :
POSA117 Cost-Effectiveness Analysis of Third-Line Pazopanib Versus Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02055-6&doi=10.1016/j.jval.2021.11.260
First page :
Section Title :
Open access? :
No
Section Order :
11034